Oral TB-500 is an unproven route for an inadequately studied compound. A capsule may be easier to take than an injection, but ease of use does not establish absorption, injury recovery, or safety in people.
This page focuses on oral delivery and the evidence needed to support it. It is not a dosing or purchasing guide.
First, check which molecule the name refers to
TB-500 and full-length thymosin beta-4 are often mixed together in online articles. They should not be treated as interchangeable.
Full-length thymosin beta-4 has 43 amino acids. The TB-500 evaluated in the FDA’s 2026 briefing is a related seven-amino-acid fragment. A capsule label needs to identify the actual ingredient before a study can be matched to it.
A human trial of full-length thymosin beta-4 does not establish that an oral TB-500 fragment works. The same caution applies to animal research and studies of other delivery routes.
Three questions an oral product must answer
- Does the compound remain intact? A formulation may aim to protect a peptide from digestion. Tests under selected conditions do not prove what happens in a person.
- How much reaches the body? This needs human measurements for the actual oral product. The label amount is not the absorbed amount.
- Does it improve health? A useful outcome, such as better function after an injury, needs controlled human testing. Absorption alone is not a treatment benefit.
What does the human evidence show?
The FDA review did not identify clinical studies or human exposure data for the TB-500 substances it evaluated. It also found no human studies measuring how those substances move through or act in the body.
This does not support claims that oral TB-500 has a known bioavailability, proven muscle-building effects, or an established recovery schedule. It also leaves the human safety profile poorly defined.
What about research on oral peptide delivery?
Researchers can study coatings, carriers, and other ways to deliver peptides through the gut. A paper about a delivery technology is not proof that every commercial capsule using similar language works.
Check the exact molecule, the finished formula, and the study population. A laboratory result, an animal experiment, and a controlled human trial answer different questions. Calling all of them clinical evidence hides those differences.
Is an oral dose equivalent to an injection dose?
No validated conversion is established here. Using the same number of milligrams does not make the routes equivalent. Splitting a weekly injection example into daily capsules also does not create a tested oral regimen.
Our TB-500 dosage reference explains example vial math and its limits. It should not be used to set a capsule dose. This page does not recommend titration or an oral schedule.
Does a capsule remove the safety concerns?
A capsule avoids needles and injection-site risks. It does not establish the safety of the compound, its interactions, or long-term use. Without adequate human data, it is not reasonable to call serious harms rare or the product generally well tolerated.
Product identity, strength, and contamination are separate questions from clinical benefit. Reviews, raw-material purity results, and seller claims cannot answer all of them. A research-only label is not evidence of safe human use.
Common claims to check
- Faster muscle or tendon repair: look for a human trial of the exact oral product.
- Heart or brain protection: work on related molecules or animal models does not prove an oral treatment benefit.
- Higher testosterone: a benefit from oral TB-500 is not established.
- Proven safe because it is related to a natural peptide: a relationship to a body substance is not a safety test.
For an injury or persistent symptoms, discuss the diagnosis and established care options with a qualified clinician. For other forms, read our TB-500 nasal spray evidence review. For combined capsules, see BPC-157/TB-500 capsule claims and evidence.
